Pacira BioSciences, Inc. 8-K

What Happened
Pacira BioSciences, Inc. (PCRX) filed a Form 8‑K on January 8, 2026 to report that it issued a press release announcing preliminary, unaudited revenue for the quarter and year ended December 31, 2025. The full text of the press release was furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: January 8, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Scope: Preliminary, unaudited revenue figures were provided for the fourth quarter and the full year ended December 31, 2025.
• Press release: The announcement was furnished as Exhibit 99.1 to the Current Report on Form 8‑K.
• Signature: Report signed by Kristen Williams, Chief Administrative Officer and Secretary.

Why It Matters
A preliminary revenue announcement gives investors an early view of Pacira’s sales performance for Q4 and full-year 2025, which can be material to assessments of the company’s near-term financial health. Because the figures are preliminary and unaudited, they may be revised when Pacira releases its final audited results and broader financial disclosures (e.g., quarterly/annual report). Investors should watch for the company’s forthcoming detailed financial report and disclosures for confirmed figures and context.